A Multicenter, Randomized, Open-lable, Parallel-controlled, Phase I/II Trial to Study Efficacy and Safety of Partial Substitution of Glucocorticoid for BDB-001 Injection in Patients With ANCA-associated Vasculitis
Latest Information Update: 28 Aug 2024
At a glance
- Drugs BDB 001 Beijing Defengrei Biotechnology (Primary) ; Cyclophosphamide; Prednisone
- Indications Granulomatosis with polyangiitis; Vasculitis
- Focus Therapeutic Use
- Sponsors Staidson Beijing BioPharmaceuticals
- 11 Oct 2023 Planned number of patients changed from 60 to 100.
- 11 Oct 2023 Planned End Date changed from 1 Sep 2023 to 1 Mar 2025.
- 11 Oct 2023 Planned primary completion date changed from 1 Sep 2023 to 1 Mar 2025.